IGC PHARMA INC (IGC)

US45408X3089 - Common Stock

0.37  +0 (+0.54%)

After market: 0.36 -0.01 (-2.7%)

Fundamental Rating

1

Taking everything into account, IGC scores 1 out of 10 in our fundamental rating. IGC was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IGC have multiple concerns. IGC is valued expensive and it does not seem to be growing.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IGC has reported negative net income.
In the past year IGC has reported a negative cash flow from operations.
In the past 5 years IGC always reported negative net income.
In the past 5 years IGC always reported negative operating cash flow.

1.2 Ratios

IGC's Return On Assets of -121.22% is on the low side compared to the rest of the industry. IGC is outperformed by 80.53% of its industry peers.
The Return On Equity of IGC (-170.38%) is worse than 67.89% of its industry peers.
Industry RankSector Rank
ROA -121.22%
ROE -170.38%
ROIC N/A
ROA(3y)-84.76%
ROA(5y)-60.82%
ROE(3y)-105.88%
ROE(5y)-74.42%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of IGC (56.21%) is better than 65.26% of its industry peers.
IGC's Gross Margin has improved in the last couple of years.
IGC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y64.59%
GM growth 5Y84.65%

More info and screens

1

2. Health

2.1 Basic Checks

IGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
IGC has more shares outstanding than it did 1 year ago.
IGC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, IGC has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -12.55, we must say that IGC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IGC (-12.55) is worse than 78.42% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that IGC is not too dependend on debt financing.
IGC's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. IGC outperforms 54.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -12.55
ROIC/WACCN/A
WACC9.91%

2.3 Liquidity

A Current Ratio of 1.52 indicates that IGC should not have too much problems paying its short term obligations.
IGC's Current ratio of 1.52 is on the low side compared to the rest of the industry. IGC is outperformed by 72.11% of its industry peers.
IGC has a Quick Ratio of 1.52. This is a bad value and indicates that IGC is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.98, IGC is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 0.98

More info and screens

3

3. Growth

3.1 Past

IGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.54%, which is quite good.
IGC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.37%.
Measured over the past years, IGC shows a very negative growth in Revenue. The Revenue has been decreasing by -23.46% on average per year.
EPS 1Y (TTM)10.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.82%
Revenue 1Y (TTM)-12.37%
Revenue growth 3Y14.33%
Revenue growth 5Y-23.46%
Sales Q2Q%42.07%

3.2 Future

Based on estimates for the next years, IGC will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.30% on average per year.
IGC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.48% yearly.
EPS Next Y50.52%
EPS Next 2Y23.61%
EPS Next 3Y13.3%
EPS Next 5YN/A
Revenue Next Year-9%
Revenue Next 2Y1.66%
Revenue Next 3Y6.48%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IGC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IGC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as IGC's earnings are expected to grow with 13.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.61%
EPS Next 3Y13.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IGC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IGC PHARMA INC

NYSEARCA:IGC (12/27/2024, 6:45:40 PM)

After market: 0.36 -0.01 (-2.7%)

0.37

+0 (+0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)02-12 2025-02-12
Inst Owners21.66%
Inst Owner ChangeN/A
Ins Owners3.26%
Ins Owner Change-0.94%
Market Cap28.66M
Analysts80
Price Target3.7 (900%)
Short Float %1.44%
Short Ratio3.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.69%
Min EPS beat(2)-14.37%
Max EPS beat(2)23.75%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-40.88%
Max Revenue beat(2)38.04%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.08%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-15.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.22
P/FCF N/A
P/OCF N/A
P/B 3.88
P/tB 5.14
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.02
BVpS0.1
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -121.22%
ROE -170.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.21%
FCFM N/A
ROA(3y)-84.76%
ROA(5y)-60.82%
ROE(3y)-105.88%
ROE(5y)-74.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y64.59%
GM growth 5Y84.65%
F-Score3
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 98.9%
Cap/Sales 53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.52
Quick Ratio 0.98
Altman-Z -12.55
F-Score3
WACC9.91%
ROIC/WACCN/A
Cap/Depr(3y)96.21%
Cap/Depr(5y)762.55%
Cap/Sales(3y)97.14%
Cap/Sales(5y)115.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.82%
EPS Next Y50.52%
EPS Next 2Y23.61%
EPS Next 3Y13.3%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.37%
Revenue growth 3Y14.33%
Revenue growth 5Y-23.46%
Sales Q2Q%42.07%
Revenue Next Year-9%
Revenue Next 2Y1.66%
Revenue Next 3Y6.48%
Revenue Next 5YN/A
EBIT growth 1Y21.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.45%
OCF growth 3YN/A
OCF growth 5YN/A